US · INVA
Innoviva, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Burlingame, CA 94010
- Website
- inva.com
Price · as of 2025-12-31
$23.11
Market cap 1.48B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $106.32 | +360.06% |
| Intrinsic Value(DCF) | $13.36 | -42.19% |
| Graham-Dodd Method(GD) | $37.25 | +61.2% |
| Graham Formula(GF) | $104.30 | +351.31% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $13.51 | $26.64 | $0.00 | $0.00 | $0.00 |
| 2012 | $18.64 | $69.45 | $1,595.38 | $0.69 | $0.00 |
| 2013 | $26.15 | $36.19 | $0.98 | $0.00 | $140.12 |
| 2014 | $16.84 | $34.55 | $0.11 | $0.00 | $0.00 |
| 2015 | $12.42 | $71.89 | $48.34 | $0.00 | $0.00 |
| 2016 | $12.67 | $85.64 | $0.00 | $0.00 | $80.61 |
| 2017 | $16.24 | $76.25 | $0.00 | $3.96 | $85.31 |
| 2018 | $14.01 | $78.74 | $0.00 | $21.10 | $107.54 |
| 2019 | $13.29 | $76.70 | $1.99 | $10.87 | $12.64 |
| 2020 | $12.04 | $85.04 | $1.21 | $16.40 | $79.44 |
| 2021 | $18.87 | $109.08 | $0.36 | $21.25 | $77.16 |
| 2022 | $10.79 | $63.07 | $3.40 | $23.10 | $0.00 |
| 2023 | $14.84 | $70.11 | $3.76 | $23.77 | $5.52 |
| 2024 | $17.64 | $89.73 | $7.51 | $12.60 | $8.60 |
| 2025 | $22.83 | $106.32 | $7.91 | $37.25 | $104.30 |
AI valuation
Our deep-learning model estimates Innoviva, Inc.'s (INVA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $106.32
- Current price
- $23.11
- AI upside
- +360.06%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$13.36
-42.19% upside
Graham-Dodd
$37.25
+61.2% upside
Graham Formula
$104.30
+351.31% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| INVA | Innoviva, Inc. | $23.11 | 1.48B | +360% | -42% | +61% | +351% | 5.67 | 1.31 | 3.62 | 2.57 | 0.69 | 1.58 | 72.33% | 38.52% | 63.78% | 29.09% | 20.10% | 18.47% | 0.00 | 9.81 | 14.64 | 11.79 | -1.44 | 81667.00% | 1852.00% | 392.00% | 12.73% | 3.96 | 28.97% | 0.00% | 0.00% | 45.61% | 6.03 | 5.04 | 2.32 | 3.32 |
| ATAI | Atai Beckley N.V | $3.63 | 684.71M | +564% | -83% | — | — | -1.61 | 2.08 | 785.20 | -1.41 | -0.59 | 2.15 | 100.00% | -33341.23% | -48463.96% | -83.53% | -126.85% | -66.27% | 0.21 | -32.87 | 3.21 | 2.55 | -0.05 | 27200.00% | -191.00% | -257.00% | -34.13% | -3.30 | -102.19% | 0.00% | 0.00% | 0.00% | -1.99 | -2.47 | 663.04 | -4.47 |
| CVAC | CureVac N.V. | $4.66 | 1.05B | +3,460% | -35% | +67% | +15,600% | 3.05 | 0.84 | 1.09 | 0.65 | — | 0.87 | 80.23% | 33.20% | 30.30% | 31.46% | 74.77% | 23.99% | 0.06 | — | 7.28 | 7.16 | -2.11 | -16102.00% | 89554.00% | -12582.00% | 14.31% | 1.41 | 41.31% | 0.00% | 0.00% | 14.10% | 0.77 | 1.64 | 0.25 | 2.92 |
| DNTH | Dianthus Therapeutics, In… | $55.19 | 2B | -29% | -75% | — | — | -9.42 | 2.27 | 128.39 | -5.19 | — | 2.27 | 100.00% | -1633.74% | -1362.77% | -32.60% | -273.59% | -30.71% | 0.00 | — | 15.22 | 14.96 | 0.21 | -6982.00% | 12063.00% | 11175.00% | -9.78% | -4.24 | -210.26% | 0.00% | 0.00% | 0.00% | -5.17 | -6.73 | 84.49 | 21.62 |
| ELVN | Enliven Therapeutics, Inc… | $29.69 | 1.76B | — | — | — | — | -11.10 | 3.19 | — | -6.48 | — | 3.19 | 0.00% | — | — | -32.04% | 1991.13% | -29.79% | 0.00 | — | 19.99 | 19.69 | 1.19 | -597.00% | — | 1924.00% | -7.41% | -4.60 | 1394.71% | 0.00% | 0.00% | 2.46% | -6.46 | -9.22 | — | 36.28 |
| IMTX | Immatics N.V. | $10.34 | 1.39B | +1,496% | -51% | -32% | +199% | 28.44 | 0.75 | 2.78 | -4.51 | — | 0.76 | 100.00% | -24.78% | 9.77% | 3.80% | 27.69% | 2.52% | 0.03 | -43.58 | 9.26 | 8.99 | -6.40 | -11167.00% | 18860.00% | 127096.00% | -40.32% | -2.32 | 175.55% | 0.00% | 0.00% | 4.04% | 4.03 | 0.89 | -1.00 | 1.96 |
| INBX | Inhibrx Biosciences, Inc. | $74.13 | 1.08B | +370% | -93% | +699% | — | 0.12 | 1.47 | 982.91 | 0.03 | — | 1.47 | -1042.50% | -165724.00% | 843786.00% | 1905.92% | 1880.87% | 690.69% | 0.06 | -24.57 | 3.94 | 3.76 | -0.08 | -237695.00% | -8889.00% | -45.00% | -100.22% | -4.77 | 1117.95% | 0.00% | 0.00% | 39.05% | -0.16 | -0.26 | 260.17 | -3.58 |
| MDXG | MiMedx Group, Inc. | $4.89 | 724.22M | +613% | +792% | -34% | +83% | 14.85 | 2.81 | 1.72 | 6.71 | 103.93 | 3.23 | 82.56% | 15.26% | 11.60% | 21.61% | 45.59% | 16.02% | 0.01 | 35.83 | 4.32 | 3.76 | -1.99 | 1429.00% | 1999.00% | 1311.00% | 10.12% | 1.15 | 71.03% | 0.00% | 0.00% | 12.22% | 8.71 | 7.63 | 1.33 | 7.43 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| RLAY | Relay Therapeutics, Inc. | $10.26 | 1.78B | +180% | -62% | — | — | -6.08 | 2.96 | 109.40 | -5.44 | — | 2.96 | 76.83% | -1971.59% | -1800.58% | -41.12% | -108.03% | -37.05% | 0.06 | — | 22.61 | 3.28 | 0.17 | -3178.00% | 5344.00% | -608.00% | -14.04% | -9.21 | -84.17% | 0.00% | 0.00% | 0.06% | -5.38 | -6.90 | 106.04 | 13.52 |
| SNDX | Syndax Pharmaceuticals, I… | $21.71 | 1.89B | +262% | +64,186% | — | — | -6.72 | 29.67 | 11.13 | -6.06 | — | 29.67 | 95.96% | -158.45% | -165.60% | -161.82% | 196.12% | -45.50% | 0.00 | -8.08 | 4.40 | 3.60 | 0.54 | -1153.00% | 62784.00% | 1756.00% | -16.85% | -2.69 | 232.09% | 0.00% | 0.00% | 17.03% | -5.58 | -4.71 | 8.84 | -1.10 |
About Innoviva, Inc.
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
- CEO
- Pavel Raifeld
- Employees
- 127
- Beta
- 0.45
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($13.36 ÷ $23.11) − 1 = -42.19% (DCF, example).